Ignite Creation Date:
2024-05-06 @ 8:10 AM
Last Modification Date:
2024-10-26 @ 11:57 AM
Study NCT ID:
NCT02688881
Status:
COMPLETED
Last Update Posted:
2022-06-15
First Post:
2016-02-18
Brief Title:
Study to Evaluate the Safety and Efficacy of Sirolimus in Subject With Refractory Solid Tumors
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Study Overview
Official Title:
Study to Evaluate the Safety and Efficacy of Sirolimus in Subject With Refractory Solid Tumors
Status:
COMPLETED
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single arm pilot study of sirolimus in patient with Phosphatidylinositide-3-kinase PIK3CA mutation PIK3CA amplification PIK3CA-AKT pathway aberration Refractory solid tumor andor specific sensitivity to mTOR inhibitors by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy
sirolimus 1mg will be administered orally daily To investigate the efficacy and safety of sirolimus in patient with Refractory solid tumor
sirolimus 1mg will be administered orally daily To investigate the efficacy and safety of sirolimus in patient with Refractory solid tumor
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None